C. Rankin

发表

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)

K. Owzar, M. Glabbeke, C. Rankin, 2007 .

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

K. Owzar, M. Bertagnolli, J. Fletcher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

H. Lenz, A. El-Khoueiry, C. Blanke, 2012, Investigational New Drugs.

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation

C. Ulrich, A. Benson, H. Lenz, 2015, Clinical Cancer Research.

External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high‐grade glioma

M. Berger, K. Stelzer, R. Livingston, 2008, Cancer.

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

R. Holcombe, H. Lenz, A. El-Khoueiry, 2011, Cancer Chemotherapy and Pharmacology.

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

F. Appelbaum, C. Rankin, C. Willman, 2000, Leukemia research.

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.

A. Klein-Szanto, D. Gandara, J. Testa, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 Southwest Oncology Group‐directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas

J. Goldblum, G. Demetri, M. von Mehren, 2012, Cancer.

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

K. Stelzer, F. Kabbinavar, C. Russell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors

D. Sargent, N. Foster, M. O’connell, 2010, Clinical Cancer Research.

Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM).

D. Gandara, C. Rankin, E. Borden, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149)

C. Rankin, K. Albain, H. Carraway, 2008, Journal of Neuro-Oncology.

Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST).

G. T. Budd, R. Randall, S. Schuetze, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas

P. Philip, H. Lenz, A. El-Khoueiry, 2007 .

Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500)

F. Appelbaum, S. Dakhil, C. Rankin, 2007, American journal of hematology.

Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811).

G. Barger, C. Rankin, E. Rushing, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.

F. Appelbaum, C. Rankin, D. Head, 2000, Leukemia research.

Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies.

F. Appelbaum, C. Rankin, D. Head, 1996, Leukemia.

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

M. van Glabbeke, R. Sciot, A. Lazar, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

J. Crowley, G. Demetri, R. Maki, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

C. Blanke, C. Rankin, J. Abbruzzese, 2009, Investigational New Drugs.

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

H. Lenz, A. El-Khoueiry, C. Rankin, 2014, British Journal of Cancer.

Characterization and Use of an Antibody Detecting the CBFβ-SMMHC Fusion Protein in inv(16)/t(16;16)-Associated Acute Myeloid Leukemias

M. Slovak, C. Rankin, C. Willman, 1998 .

Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505

J. Goldblum, G. Demetri, C. Rankin, 2008 .

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033

J. Crowley, K. Owzar, J. Fletcher, 2017, JAMA oncology.

A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001

K. Stelzer, D. Moore, A. Sloan, 2015, International Journal of Clinical Oncology.

TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL ONCOLOGISTS FROM: SWOG Operations Office RE: IND Safety Reports for IMC-A12 MEMORANDUM

H. Gundacker, C. Tangen, C. Rankin, 2011 .

Polymorphisms in folate‐metabolizing enzymes and response to 5‐fluorouracil among patients with stage II or III rectal cancer (INT‐0144; SWOG 9304)

C. Ulrich, H. Lenz, K. Makar, 2014, Cancer.

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.

J. Crowley, G. Demetri, C. Blanke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.

K. Owzar, J. Fletcher, G. Demetri, 2014 .

C. Rankin, R. Nagle, L. Garland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma.

H. Lenz, A. El-Khoueiry, C. Rankin, 2012 .